Technologies

The technology, developed by CNR-ICB, is based on an innovative bioprocess called "Caphnophilic (CO2-requiring) Lactic Fermentation (CLF)”, developed in the hyperthermophilic bacterium Thermotoga neapolitana (EP patent: EP2948556B1), which allows the production of "green" hydrogen and capture and valorization of CO2 in L -lactic acid (98% e.e.).

Direct quantification of the percentage of arabica in roasted and ground coffee blends of arabica/robusta by High Resolution Nuclear Magnetic Resonance spectroscopy (NMR), in solution and multivariate statistical analysis. Particularly, the metabolites content present in water extracts of coffee is analyzed and compared with NMR data of our database.

The containers for plants and the like have different shapes, an open top to facilitate irrigation and material supply; a base that includes one or more holes to facilitate proper water drainage and to ensure ventilation for the rooting apparatus. An inconvenience of these containers is related to their placement in outdoor environments without roofs: in the presence of "unfavorable" climatic conditions, excessive exposure to rain water rather than excessive exposure to the sun, these containers expose plants to a series of problems.

Method for extracting, with high yield, phycobiliproteins from cyanobacterial and/or algal biomass, obtaining aqueous extracts characterized by high concentration of pigments (4-5 mg/mL)  and a purity, at least equal to food/cosmetic grade (P≥2).

Celiac disease and non-celiac gluten sensitivity affect a large portion of the world population. Furthermore, the percentage of people who adopt the gluten free diet is constantly increasing because it is perceived to be healthier. We have previously developed a food grade enzymatic procedure (transamidation) for wheat flour capable of making gluten unable to induce the inflammatory response in the intestine of celiac disease patients.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.